Trevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a report issued on Friday,Benzinga reports. They currently have a $21.00 price objective on the stock.

A number of other brokerages have also commented on TRVI. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a research report on Thursday, December 12th. HC Wainwright lifted their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research report on Thursday, December 12th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $9.31.

Trevi Therapeutics Stock Up 0.2 %

Trevi Therapeutics stock opened at $4.30 on Friday. The stock has a 50-day simple moving average of $4.14 and a 200 day simple moving average of $3.50. Trevi Therapeutics has a 12-month low of $2.30 and a 12-month high of $5.05. The stock has a market capitalization of $330.52 million, a price-to-earnings ratio of -9.77 and a beta of 0.90.

Hedge Funds Weigh In On Trevi Therapeutics

Institutional investors have recently modified their holdings of the stock. Summit Investment Advisors Inc. grew its position in shares of Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after buying an additional 2,894 shares during the period. BNP Paribas Financial Markets grew its position in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after buying an additional 6,764 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Trevi Therapeutics during the 4th quarter worth about $49,000. Squarepoint Ops LLC acquired a new position in shares of Trevi Therapeutics during the 4th quarter worth about $58,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Trevi Therapeutics during the 4th quarter worth about $66,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.